A Randomised, 3 Period, Single Dose, Open-label Crossover Study to Evaluate the Systemic Exposure of AZD8154 While Administered Via Inhalation Using a Nebuliser Formulation and a Monodose Dry Powder Inhaler (DPI) Formulation in Healthy Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs AZD-8154 (Primary) ; AZD-8154 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 11 Dec 2020 Status changed from suspended to discontinued due to need for evaluation of emerging pre-clinical toxicology findings.
- 25 Sep 2020 Status changed from recruiting to suspended as per need for evaluation of emerging pre-clinical toxicology findings
- 29 Jul 2020 Status changed from not yet recruiting to recruiting.